Therefore, to evaluate whether CX4945 could enhance the efficacy of anti‐PD‐1 therapy in tumors resistant to it, we administered CX4945 in a TC‐1‐OVA transplantation tumor model in mice with tumors that continued to grow rapidly despite two times of anti‐PD‐1 therapy. This evidence concerns the gene PDCD1 and neoplasm.